CO6731132A2 - Comprimido de desintegración oral - Google Patents
Comprimido de desintegración oralInfo
- Publication number
- CO6731132A2 CO6731132A2 CO13176405A CO13176405A CO6731132A2 CO 6731132 A2 CO6731132 A2 CO 6731132A2 CO 13176405 A CO13176405 A CO 13176405A CO 13176405 A CO13176405 A CO 13176405A CO 6731132 A2 CO6731132 A2 CO 6731132A2
- Authority
- CO
- Colombia
- Prior art keywords
- fine granules
- active ingredient
- pharmaceutically active
- lansoprazole
- controlled release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporciona un comprimido de desintegración oral obtenido por compresión de gránulos finos que muestran una liberación controlada de lansoprazol y un aditivo, que es capaz de suprimir la rotura de los gránulos finos durante la compresión y puede controlar la liberación de lansoprazol durante un tiempo prolongado y puede mantener una concentración terapéuticamente efectiva durante un tiempo prolongado y muestra una propiedad de desintegración en la cavidad oral superior.Un comprimido de desintegración oral que contiene (i) gránulos finos que muestran una liberación controlada de un ingrediente farmacéuticamente activo, que contiene, gránulos finos con un ingrediente farmacéuticamente activo, y una capa de revestimiento con copolímero de ácidos metacrílico/acrilato de metilo/metacrilato de metilo, en donde los gránulos finos que contienen un ingrediente farmacéuticamente activo están recubiertos con más del 80% en peso y no más del 300% en peso del copolímero y(ii) gránulos finos que muestran una liberación controlada de un ingrediente farmacéuticamente activo, que contiene el ingrediente farmacéuticamente activo y una capa de revestimiento que comprende (a) un copolímero de acrilato de etilo/metacrilato de metilo y (b) uno o más tipos de polímeros seleccionados del grupo que consiste en copolímero de ácido metacrílico/acrilato de etilo, ftalato de hipromelosa, carboximetiletilcelulosa, acetato ftalato de polivinilo, acetato succinato de hidroxipropilmetilcelulosa y acetato ftalato de celulosa, en donde los gránulos finos (i) y gránulos finos (ii) tienen un tamaño de partícula medio de no más del 500 pm y el ingrediente farmacéuticamente activo es lansoprazol o una de sus formas ópticamente activas o una de sus sales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061427384P | 2010-12-27 | 2010-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6731132A2 true CO6731132A2 (es) | 2013-08-15 |
Family
ID=45509604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO13176405A CO6731132A2 (es) | 2010-12-27 | 2013-07-25 | Comprimido de desintegración oral |
Country Status (23)
Country | Link |
---|---|
US (1) | US20130273157A1 (es) |
EP (1) | EP2658530A2 (es) |
JP (1) | JP2014501224A (es) |
KR (1) | KR20140007364A (es) |
CN (1) | CN103402500A (es) |
AR (1) | AR084610A1 (es) |
AU (1) | AU2011350396A1 (es) |
BR (1) | BR112013014875A2 (es) |
CA (1) | CA2823166C (es) |
CL (1) | CL2013001793A1 (es) |
CO (1) | CO6731132A2 (es) |
CR (1) | CR20130327A (es) |
EA (1) | EA028217B1 (es) |
EC (1) | ECSP13012718A (es) |
MA (1) | MA34768B1 (es) |
MX (1) | MX2013007588A (es) |
PE (1) | PE20141115A1 (es) |
SG (2) | SG190905A1 (es) |
TN (1) | TN2013000220A1 (es) |
TW (1) | TW201304823A (es) |
UY (1) | UY33841A (es) |
WO (1) | WO2012091153A2 (es) |
ZA (1) | ZA201304617B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009113703A2 (en) | 2008-03-11 | 2009-09-17 | Takeda Pharmaceutical Company Limited | Orally-disintegrating solid preparation |
PT3738434T (pt) | 2011-12-28 | 2023-11-13 | Global Blood Therapeutics Inc | Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos |
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
GB201303781D0 (en) | 2013-03-04 | 2013-04-17 | Gauthier Pierre Pascal | Oral timer device and method of using same |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CN111454200A (zh) | 2013-03-15 | 2020-07-28 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
SG10201802911RA (en) | 2013-03-15 | 2018-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
SI3102208T1 (sl) | 2014-02-07 | 2021-07-30 | Global Blood Therapeutics, Inc. | Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida |
KR20170083535A (ko) | 2014-11-14 | 2017-07-18 | 젬파이어 세러퓨틱스 인코포레이티드 | α,ω-다이카복실산-말단 다이알케인 에터를 제조하기 위한 방법 및 중간체 |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
TWI778983B (zh) * | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
US20190008779A1 (en) * | 2017-05-11 | 2019-01-10 | Gemphire Therapeutics Inc. | Gemcabene compositions and methods of use thereof |
BR112020000318A2 (pt) | 2017-07-10 | 2020-07-14 | Takeda Pharmaceutical Company Limited | preparação |
CN108576205B (zh) * | 2018-03-22 | 2022-01-04 | 湖北省农业科学院农产品加工与核农技术研究所 | 一种草莓联合干燥的处理方法 |
US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
JPH072761B2 (ja) | 1985-03-20 | 1995-01-18 | 不二パウダル株式会社 | 微結晶セルロ−ス球形顆粒及びその製造法 |
JPS62277322A (ja) | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
DE69331839T2 (de) | 1992-01-29 | 2002-12-12 | Takeda Chemical Industries Ltd | Schnellösliche Tablette und ihre Herstellung |
JP2919771B2 (ja) | 1995-04-17 | 1999-07-19 | 佐藤製薬株式会社 | 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤 |
JPH0948726A (ja) | 1995-08-07 | 1997-02-18 | Tanabe Seiyaku Co Ltd | 口腔内速崩壊性製剤およびその製法 |
JP3828648B2 (ja) | 1996-11-14 | 2006-10-04 | 武田薬品工業株式会社 | 2−(2−ピリジルメチルスルフィニル)ベンズイミダゾール系化合物の結晶およびその製造法 |
TW385306B (en) | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
CN1195500C (zh) | 1998-05-18 | 2005-04-06 | 武田药品工业株式会社 | 可口腔崩解的片剂 |
CA2581111A1 (en) | 1998-07-28 | 2000-02-10 | Takeda Pharmaceutical Company Limited | Rapidly disintegrable solid preparation |
TWI289557B (en) | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
CA2407208C (en) | 2000-04-28 | 2010-08-17 | Takeda Chemical Industries, Ltd. | Process for producing optically active sulfoxide derivative |
ES2511774T3 (es) | 2000-05-15 | 2014-10-23 | Takeda Pharmaceutical Company Limited | Formas cristalinas de (R)-lansoprazol |
HU229356B1 (en) | 2000-12-01 | 2013-11-28 | Takeda Pharmaceutical | Process for the crystallization of (r)- or (s)-lansoprazole |
JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
CN1964704A (zh) * | 2004-03-03 | 2007-05-16 | 特瓦制药工业有限公司 | 包含酸不稳定药物的稳定药用组合物 |
JP2009519334A (ja) * | 2005-12-20 | 2009-05-14 | テバ ファーマシューティカル インダストリーズ リミティド | ランソプラゾール経口崩壊錠剤 |
US20070141151A1 (en) * | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
EP1837016A3 (en) * | 2006-03-08 | 2008-01-02 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical multiple-unit composition |
JP5366558B2 (ja) * | 2006-12-28 | 2013-12-11 | 武田薬品工業株式会社 | 口腔内崩壊性固形製剤 |
WO2009113703A2 (en) * | 2008-03-11 | 2009-09-17 | Takeda Pharmaceutical Company Limited | Orally-disintegrating solid preparation |
US20100015239A1 (en) * | 2008-07-17 | 2010-01-21 | Ahmed Salah U | Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same |
-
2011
- 2011-12-26 AU AU2011350396A patent/AU2011350396A1/en not_active Abandoned
- 2011-12-26 EP EP11811174.9A patent/EP2658530A2/en not_active Withdrawn
- 2011-12-26 TW TW100148775A patent/TW201304823A/zh unknown
- 2011-12-26 CA CA2823166A patent/CA2823166C/en active Active
- 2011-12-26 KR KR1020137019795A patent/KR20140007364A/ko not_active Application Discontinuation
- 2011-12-26 MX MX2013007588A patent/MX2013007588A/es not_active Application Discontinuation
- 2011-12-26 SG SG2013040944A patent/SG190905A1/en unknown
- 2011-12-26 JP JP2013529237A patent/JP2014501224A/ja active Pending
- 2011-12-26 US US13/997,862 patent/US20130273157A1/en not_active Abandoned
- 2011-12-26 BR BR112013014875A patent/BR112013014875A2/pt active Search and Examination
- 2011-12-26 WO PCT/JP2011/080568 patent/WO2012091153A2/en active Application Filing
- 2011-12-26 EA EA201390981A patent/EA028217B1/ru not_active IP Right Cessation
- 2011-12-26 CN CN2011800685821A patent/CN103402500A/zh active Pending
- 2011-12-26 SG SG10201602311XA patent/SG10201602311XA/en unknown
- 2011-12-26 UY UY0001033841A patent/UY33841A/es not_active Application Discontinuation
- 2011-12-26 PE PE2013001471A patent/PE20141115A1/es not_active Application Discontinuation
- 2011-12-27 AR ARP110104955A patent/AR084610A1/es unknown
-
2013
- 2013-05-24 TN TNP2013000220A patent/TN2013000220A1/fr unknown
- 2013-06-19 CL CL2013001793A patent/CL2013001793A1/es unknown
- 2013-06-21 ZA ZA2013/04617A patent/ZA201304617B/en unknown
- 2013-06-25 EC ECSP13012718 patent/ECSP13012718A/es unknown
- 2013-06-27 CR CR20130327A patent/CR20130327A/es not_active Application Discontinuation
- 2013-06-28 MA MA36063A patent/MA34768B1/fr unknown
- 2013-07-25 CO CO13176405A patent/CO6731132A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EA028217B1 (ru) | 2017-10-31 |
AU2011350396A1 (en) | 2013-07-11 |
PE20141115A1 (es) | 2014-09-12 |
CA2823166C (en) | 2019-04-09 |
CA2823166A1 (en) | 2012-07-05 |
MX2013007588A (es) | 2013-08-09 |
EP2658530A2 (en) | 2013-11-06 |
CR20130327A (es) | 2013-08-22 |
SG10201602311XA (en) | 2016-04-28 |
BR112013014875A2 (pt) | 2016-10-18 |
ZA201304617B (en) | 2014-08-27 |
KR20140007364A (ko) | 2014-01-17 |
EA201390981A1 (ru) | 2014-07-30 |
AR084610A1 (es) | 2013-05-29 |
CL2013001793A1 (es) | 2013-12-06 |
WO2012091153A2 (en) | 2012-07-05 |
JP2014501224A (ja) | 2014-01-20 |
ECSP13012718A (es) | 2013-12-31 |
MA34768B1 (fr) | 2013-12-03 |
TW201304823A (zh) | 2013-02-01 |
UY33841A (es) | 2012-07-31 |
CN103402500A (zh) | 2013-11-20 |
TN2013000220A1 (en) | 2014-11-10 |
WO2012091153A3 (en) | 2012-09-07 |
SG190905A1 (en) | 2013-07-31 |
US20130273157A1 (en) | 2013-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6731132A2 (es) | Comprimido de desintegración oral | |
EA201892836A1 (ru) | Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением | |
PE20211976A1 (es) | Composiciones de liberacion retardada de linaclotida | |
PE20091620A1 (es) | Preparacion solida de desintegracion oral | |
PE20130574A1 (es) | Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
JP2013522219A5 (es) | ||
EA201400172A1 (ru) | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства | |
PE20131126A1 (es) | Forma de dosificacion resistente a alteracion que comprende un polimero anionico | |
EA201290026A1 (ru) | Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid) | |
UY29193A1 (es) | Nuevas formulaciones de tabletas de liberación modificada para inhibidores de bomba de protón | |
NZ723860A (en) | Pharmaceutical compositions of therapeutically active compounds and their uses | |
MX2013014788A (es) | Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos. | |
JP2011519967A5 (es) | ||
RU2008130892A (ru) | Твердое лекарственное средство с контролируемым высвобождением | |
UY29192A1 (es) | Nuevas formulaciones de comprimidos de liberación modificada para inhibidores de bomba de protón | |
NZ605601A (en) | Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof | |
CO6640256A2 (es) | Tableta enterica | |
EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
CO6382109A2 (es) | Formulación de depósito de octreotida con niveles de exposición constantemente altos | |
EA201390979A1 (ru) | Композиции бензимидазолов с модифицированным высвобождением | |
AR071970A1 (es) | Composicion de liberacion pulsatil de sildenafil y proceso para prepararla | |
PE20110943A1 (es) | Formulacion oral solida de alisquireno | |
EA201591787A1 (ru) | Таблетки совапревира | |
AR071706A1 (es) | Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion. | |
CA2797809A1 (en) | Enteric tablet |